<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr J</journal-id><journal-id journal-id-type="iso-abbrev">Nutr J</journal-id><journal-title-group><journal-title>Nutrition Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2891</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29310653</article-id><article-id pub-id-type="pmc">5757297</article-id><article-id pub-id-type="publisher-id">314</article-id><article-id pub-id-type="doi">10.1186/s12937-018-0314-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of soy lecithin on fatigue and menopausal symptoms in middle-aged women: a randomized, double-blind, placebo-controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hirose</surname><given-names>Asuka</given-names></name><address><email>a-kacrm@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5577-0094</contrib-id><name><surname>Terauchi</surname><given-names>Masakazu</given-names></name><address><email>teragyne@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Osaka</surname><given-names>Yurika</given-names></name><address><email>120122ms@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Akiyoshi</surname><given-names>Mihoko</given-names></name><address><email>akiyoshi@shonan.bunkyo.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Kiyoko</given-names></name><address><email>kiyoko2226@nifty.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Miyasaka</surname><given-names>Naoyuki</given-names></name><address><email>n.miyasaka.gyne@tmd.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1014 9130</institution-id><institution-id institution-id-type="GRID">grid.265073.5</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>Tokyo Medical and Dental University, </institution></institution-wrap>Yushima 1-5-45, Bunkyo, Tokyo, 113-8510 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1014 9130</institution-id><institution-id institution-id-type="GRID">grid.265073.5</institution-id><institution>Department of Women&#x02018;s Health, </institution><institution>Tokyo Medical and Dental University, </institution></institution-wrap>Yushima 1-5-45, Bunkyo, Tokyo, 113-8510 Japan </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>17</volume><elocation-id>4</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Lecithin is a complex mixture of phospholipids which compose lipid bilayer cell membranes. Lipid replacement therapy, or administration of phospholipids for the purpose of repairing the dmaged cell membranes, had been shown to alleviate fatigue. The present study aimed to investigate the effect of soy lecithin on fatigue in middle-aged women, as well as other menopausal symptoms and various health parameters.</p></sec><sec><title>Methods</title><p id="Par2">This randomized, double-blind, placebo-controlled study included 96 women aged 40 to 60&#x000a0;years who complained of fatigue. The participants were randomized to receive active tablets containing high-dose (1200&#x000a0;mg/day; <italic>n</italic>&#x02009;=&#x02009;32) or low-dose (600&#x000a0;mg/day; <italic>n</italic>&#x02009;=&#x02009;32) soy lecithin, or placebo (<italic>n</italic>&#x02009;=&#x02009;32), for 8&#x000a0;weeks. The following parameters were evaluated: age, menopausal status, lifestyle factors, physical and psychological symptoms of menopause, subjective symptoms of insomnia and fatigue, body composition, cardiovascular parameters, and physical activities and objective sleep states obtained from actigraphy before and 4 and 8&#x000a0;weeks after treatment. Fatigue was evaluated using the Profile of Mood States (POMS)-brief, Menopausal Health-Related Quality of Life questionnaire, Chalder Fatigue Scale, and Brief Fatigue Inventory.</p></sec><sec><title>Results</title><p id="Par3">Eighty-nine women completed the study. There were no significant differences in the changes in Chalder Fatigue Scale score (placebo vs low-dose vs high-dose groups: &#x02212;2.9&#x02009;&#x000b1;&#x02009;1.1, &#x02212;3.2&#x02009;&#x000b1;&#x02009;1.1, and &#x02212;3.5&#x02009;&#x000b1;&#x02009;1.0; <italic>P</italic>&#x02009;=&#x02009;0.79). On the other hand, the improvements were greater in the high-dose group compared with the placebo group concerning vigor scores in the POMS-brief (1.9&#x02009;&#x000b1;&#x02009;0.7 vs 0.2&#x02009;&#x000b1;&#x02009;0.6; <italic>P</italic>&#x02009;=&#x02009;0.02), diastolic blood pressure (&#x02212;4.1&#x02009;&#x000b1;&#x02009;1.8 vs 1.2&#x02009;&#x000b1;&#x02009;1.9; <italic>P</italic>&#x02009;=&#x02009;0.05), and cardio-ankle vascular index (&#x02212;0.4&#x02009;&#x000b1;&#x02009;0.2 vs 0.07&#x02009;&#x000b1;&#x02009;0.1; <italic>P</italic>&#x02009;=&#x02009;0.03) after 8&#x000a0;weeks of treatment.</p></sec><sec><title>Conclusions</title><p id="Par4">High-dose (1200&#x000a0;mg/day) soy lecithin not only increases vigor, but also lowers the diastolic blood pressure and cardio-ankle vascular index in middle-aged women who present with fatigue.</p></sec><sec><title>Trial registration</title><p id="Par5"><ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019866">UMIN-CTR UMIN000017127</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Atherosclerosis</kwd><kwd>Cardiovascular risks</kwd><kwd>Fatigue</kwd><kwd>Lipid replacement therapy</kwd><kwd>Menopausal symptoms</kwd><kwd>Psychological symptoms</kwd><kwd>Soy</kwd></kwd-group><funding-group><award-group><funding-source><institution>Kikkoman Corporation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par19">Middle-aged women are bothered by various symptoms such as hot flashes, night sweats, anxiety, depression, insomnia, and fatigue. A previous study revealed that 86% of Japanese middle-aged women who visited our menopausal clinic felt tiredness more than once a week, and 49% felt it almost every day [<xref ref-type="bibr" rid="CR1">1</xref>]. Another study revealed that 85% of Japanese and 82% of Australian middle-aged women felt fatigue, at least to some extent [<xref ref-type="bibr" rid="CR2">2</xref>]. Compared to the patients attending a primary care clinic of whom 14% complained of fatigue [<xref ref-type="bibr" rid="CR3">3</xref>], apparently more middle-aged women are bothered by the symptom.</p><p id="Par20">Lecithin is a complex mixture of phospholipids found mainly in egg yolks, soy, and coleseeds. Phospholipids such as phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, and phosphatidyl glycerol compose the lipid bilayer of the cellular membrane structure. Membrane lipids are used for energy storage necessary for membrane biogenesis [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. The matrix of cellular membranes is formed by polar lipids, which consist of a hydrophobic and hydrophilic portion and segregate the internal and external environment [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, membrane lipids act as first and second messengers in signal transduction and molecular recognition pathways [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], implying the variability of their biological roles. The administration of fresh phospholipids to replace damaged cell membranes and restore the structure and function of the cellular membrane is called lipid replacement therapy (LRT). LRT has been shown to improve fatigue, and is expected to be effective for the treatment of degenerative diseases, metabolic syndrome, diabetes, and cardiovascular diseases [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. However, previous studies have demonstrated the effects of LRT using a supplement containing not only phospholipids but also other active ingredients. To the best of our knowledge, this study is the first to examine the effects of soy lecithin on fatigue.</p><p id="Par21">The present study aimed to investigate the effect of soy lecithin on menopausal symptoms including fatigue and other various health parameters in Japanese middle-aged women.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par22">We performed a randomized, double-blind, placebo-controlled study from February to July 2015 at the Menopause Clinic of Tokyo Medical and Dental University. The study protocol was reviewed and approved by the Tokyo Medical and Dental University Review Board, and written informed consent was obtained from all the participants. The present study was conducted in accordance with the Declaration of Helsinki.</p><p id="Par23">Ninety-six Japanese women aged 40 to 59&#x000a0;years who complained of fatigue participated in this study. Fatigue was evaluated using the item about fatigue in the Menopausal Health-Related Quality of Life (MHR-QOL) questionnaire. The participants were recruited through advertisements posted in our hospital and in the patients&#x02019; social network. Those who were receiving menopausal hormone therapy, herbal medicine, or psychotropic drugs were excluded. Collected data included age, menopausal status, lifestyle factors, physical and psychological symptoms of menopause, subjective symptoms of insomnia and fatigue, body composition, cardiovascular parameters, and physical activities and objective sleep states obtained from actigraphy. The data were evaluated before and 4 and 8&#x000a0;weeks after treatment. Regarding menopausal status, participants were classified as follows: premenopausal (regular menstrual cycles in the past 3&#x000a0;months), perimenopausal (a menstrual period within the past 12&#x000a0;months but a missed period or irregular cycles in the past 3&#x000a0;months), postmenopausal (no menstrual period in the past 12&#x000a0;months), or surgically induced menopause (hysterectomy).</p></sec><sec id="Sec4"><title>Randomization and intervention</title><p id="Par24">The participants were randomized into 1 of 3 groups to receive active tablets containing high-dose (1200&#x000a0;mg/day; <italic>n</italic>&#x02009;=&#x02009;32) or low-dose (600&#x000a0;mg/day; <italic>n</italic>&#x02009;=&#x02009;32) soy lecithin, or placebo (n&#x02009;=&#x02009;32) for 8&#x000a0;weeks. The high-dose and low-dose soy lecithin and placebo tablets, indistinguishable in shape, weight, and color, were manufactured and packaged by Kikkoman Corporation (Noda, Japan). The tablet contained phospholipids in the form of phosphatidylcholine, 24%; phosphatidylethanolamine, 20%; and phosphatidylinositol, 12%. The women were instructed to take six tablets per day after breakfast. Medication adherence was evaluated by collecting the packages of the supplements from participants. The participants were sequentially numbered, and received supplement packages with the corresponding number. The content of each package, namely high-dose or low-dose soy lecithin, or placebo, was known only by the manufacturers. Thus, allocation was concealed from both the participants and the investigators. Safety was assessed by patient-reported treatment-emergent adverse events.</p></sec><sec id="Sec5"><title>Menopausal symptoms</title><p id="Par25">Menopausal symptoms were evaluated using the Menopausal Health-Related Quality of Life (MHR-QOL) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Athens Insomnia Scale (AIS). The MHR-QOL questionnaire, developed and validated at our clinic [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], is a modification of the Women&#x02019;s Health Questionnaire [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], and contains 38 items scored on a 4-point or binary scale covering four major domains (physical symptoms, psychological symptoms, life satisfaction, and social involvement) of a woman&#x02019;s health during menopause. The HADS [<xref ref-type="bibr" rid="CR12">12</xref>] is a reliable instrument for screening clinically significant anxiety and depression in women visiting a general medicine clinic. The translated Japanese version of the HADS [<xref ref-type="bibr" rid="CR13">13</xref>] was used in the present study. The AIS was developed as a brief and easy-to-administer self-assessment questionnaire for determining the severity of insomnia defined according to the International Classification of Diseases 10th Revision. The internal consistency and test-retest reliability of the AIS have been confirmed previously [<xref ref-type="bibr" rid="CR14">14</xref>]. Detailed information about the MHR-QOL questionnaire, HADS, and AIS is provided elsewhere [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec><sec id="Sec6"><title>Fatigue and mood states</title><p id="Par26">Fatigue and mood states were evaluated by the Profile of Mood States (POMS)-brief, Chalder Fatigue Scale (CFS), and Brief Fatigue Inventory (BFI). The POMS is a psychological rating scale used to assess feelings and mood states. The original version of the POMS consists of 65 items, while the POMS-brief, a shortened version, includes 30 items covering six major domains (tension, depression, anger, vigor, fatigue, and confusion). Because the latter is easier to complete and its validity has been demonstrated [<xref ref-type="bibr" rid="CR15">15</xref>], it is now more widely used than the original form. The POMS-brief was translated into Japanese, and its reliability and validity were confirmed previously [<xref ref-type="bibr" rid="CR16">16</xref>]. The CFS is a self-administered questionnaire with 14 items which evaluates fatigue-related symptoms by using a 4-point Likert scale for the extent or frequency of the symptoms [<xref ref-type="bibr" rid="CR17">17</xref>]. Although originally developed to measure fatigue symptoms in clinical settings, the scale is now more widely used [<xref ref-type="bibr" rid="CR18">18</xref>]. The BFI, a self-rating assessment composed of 9 items using a numerical scale of 0 to 10, was developed for the rapid assessment of fatigue severity in cancer patients [<xref ref-type="bibr" rid="CR19">19</xref>]. It was translated into Japanese, and its reliability and validity were confirmed previously [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec7"><title>Body composition and cardiovascular parameters</title><p id="Par27">Height, weight, body mass index, and body composition including fat mass, and fat free mass, was assessed using a body composition analyzer (MC190-EM; Tanita, Tokyo, Japan). Cardiovascular parameters, including systolic and diastolic blood pressure, heart rate, and the cardio-ankle vascular index (CAVI), were measured using a vascular screening system (VS-1000; Fukuda Denshi Co., Tokyo, Japan).</p></sec><sec id="Sec8"><title>Physical activities and objective sleep states</title><p id="Par28">We investigated physical activities and objective sleep states using the actigraphy system that is loaded with a miniature triaxial acceleration sensor (Wrist-worn Accelerometers; Hitachi Ltd., Tokyo, Japan). It measured motion with accelerometers and sleep&#x02013;wake identification was automatically performed by using the Cole&#x02013;Kripke algorithm. The outcome measures included zero-crossing (ZC) and metabolic equivalents (METs) during the awake and sleep phase, total sleep time, day-to-day variation of sleep time, episodes of nocturnal awakening, sleep latency, and sleep efficiency. ZC is the rate of signal changes from the triaxial acceleration sensor, representing the frequency of wrist motion. METs are calculated as the ratio of metabolic rate relative to that in resting, representing the intensity of exercise. We define sleep latency as the time from time in bed to the start of identification of sleep. Sleep efficiency is calculated as pure sleep time (time in bed minus awake time) divided by time in bed. Participants were requested to wear a wrist actigraph device for 72&#x000a0;h on their non-dominant arms except during bathing time. The analysis of the actigraphy data was performed at &#x02018;blinded for peer review&#x02019;.</p></sec><sec id="Sec9"><title>Statistical analyses</title><p id="Par29">The baseline characteristics of the participants who completed the 8-week treatment were compared using one-way analysis of variance, &#x003c7;2 test, and Kruskal-Wallis test. Then, the changes from baseline to 8&#x000a0;weeks of treatment in all of the collected data were evaluated using Mann-Whitney test and unpaired t-test. All statistical analyses were performed with GraphPad Prism version 5.02 (GraphPad Software Incorporated, CA, USA). A <italic>P</italic>-value &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec10"><title>Results</title><p id="Par30">A total of 96 middle-aged women were enrolled in the study and were randomized to the high-dose (<italic>n</italic>&#x02009;=&#x02009;32), low-dose (n&#x02009;=&#x02009;32), or placebo groups (<italic>n</italic>&#x02009;=&#x02009;32); of these, 89 (94%) completed the 8-week treatment period (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). During the study period, seven women dropped out of the study. Five of them did not continue to take the supplements, and two did not have an examination at our clinic. The baseline characteristics of the participants who completed the 8-week treatment are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The group mean age ranged from 49 to 51&#x000a0;years. The proportion of women who were premenopausal, perimenopausal, postmenopausal, and had surgically induced menopause ranged from 22 to 52%, 7 to 22%, 41 to 53%, and 0 to 7%, respectively. The weight, body mass index, and body fat mass were significantly higher in the high-dose group than the other groups (<italic>P</italic>&#x02009;=&#x02009;0.018, 0.012, and 0.008, respectively).<fig id="Fig1"><label>Fig. 1</label><caption><p>Participant disposition</p></caption><graphic xlink:href="12937_2018_314_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Background characteristics of the participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo (<italic>n</italic>&#x02009;=&#x02009;32)</th><th>Low-dose lecithin (<italic>n</italic>&#x02009;=&#x02009;30)</th><th>High-dose lecithin (<italic>n</italic>&#x02009;=&#x02009;27)</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Age, y</td><td>51.2&#x02009;&#x000b1;&#x02009;5.2</td><td>50.3&#x02009;&#x000b1;&#x02009;5.8</td><td>49.3&#x02009;&#x000b1;&#x02009;4.8</td><td>0.423<sup>a</sup></td></tr><tr><td align="justify" colspan="5">Menopausal status, n (%)</td></tr><tr><td>&#x02003;Premenopausal</td><td>7 (21.9)</td><td>10 (33.3)</td><td>14 (51.9)</td><td>0.222<sup>b</sup></td></tr><tr><td>&#x02003;Perimenopausal</td><td>7 (21.9)</td><td>5 (16.7)</td><td>2 (7.4)</td><td/></tr><tr><td>&#x02003;Postmenopausal</td><td>17 (53.1)</td><td>13 (43.3)</td><td>11 (40.7)</td><td/></tr><tr><td>&#x02003;Surgically induced menopause</td><td>1 (3.1)</td><td>2 (6.7)</td><td>0 (0)</td><td/></tr><tr><td align="justify" colspan="5">Questionnaire</td></tr><tr><td>&#x02003;MHR-QOL physical symptom score</td><td>21.2&#x02009;&#x000b1;&#x02009;3.5</td><td>21.9&#x02009;&#x000b1;&#x02009;2.9</td><td>20.6&#x02009;&#x000b1;&#x02009;3.2</td><td>0.406<sup>c</sup></td></tr><tr><td>&#x02003;MHR-QOL psychological symptom score</td><td>27.1&#x02009;&#x000b1;&#x02009;8.0</td><td>29.7&#x02009;&#x000b1;&#x02009;6.7</td><td>30.0&#x02009;&#x000b1;&#x02009;5.5</td><td>0.328<sup>c</sup></td></tr><tr><td>&#x02003;HADS-anxiety subscale score</td><td>5.8&#x02009;&#x000b1;&#x02009;2.9</td><td>5.3&#x02009;&#x000b1;&#x02009;3.3</td><td>4.9&#x02009;&#x000b1;&#x02009;2.7</td><td>0.549<sup>c</sup></td></tr><tr><td>&#x02003;HADS-depression subscale score</td><td>5.5&#x02009;&#x000b1;&#x02009;3.7</td><td>4.8&#x02009;&#x000b1;&#x02009;3.7</td><td>4.7&#x02009;&#x000b1;&#x02009;3.1</td><td>0.679<sup>c</sup></td></tr><tr><td>&#x02003;AIS score</td><td>5.0&#x02009;&#x000b1;&#x02009;3.0</td><td>4.0&#x02009;&#x000b1;&#x02009;2.9</td><td>4.1&#x02009;&#x000b1;&#x02009;2.6</td><td>0.443<sup>c</sup></td></tr><tr><td>&#x02003;Chalder Fatigue Scale</td><td>18.7&#x02009;&#x000b1;&#x02009;8.3</td><td>17.1&#x02009;&#x000b1;&#x02009;5.3</td><td>17.6&#x02009;&#x000b1;&#x02009;6.6</td><td>0.628<sup>c</sup></td></tr><tr><td>&#x02003;Brief Fatigue Inventory</td><td>2.7&#x02009;&#x000b1;&#x02009;1.9</td><td>3.0&#x02009;&#x000b1;&#x02009;1.7</td><td>3.0&#x02009;&#x000b1;&#x02009;2.0</td><td>0.575<sup>c</sup></td></tr><tr><td>&#x02003;POMS-tension</td><td>6.1&#x02009;&#x000b1;&#x02009;4.9</td><td>5.5&#x02009;&#x000b1;&#x02009;4.3</td><td>4.3&#x02009;&#x000b1;&#x02009;3.1</td><td>0.461<sup>c</sup></td></tr><tr><td>&#x02003;POMS-depression</td><td>3.9&#x02009;&#x000b1;&#x02009;3.9</td><td>2.5&#x02009;&#x000b1;&#x02009;3.1</td><td>2.5&#x02009;&#x000b1;&#x02009;2.6</td><td>0.217<sup>c</sup></td></tr><tr><td>&#x02003;POMS-anger</td><td>5.1&#x02009;&#x000b1;&#x02009;4.2</td><td>3.7&#x02009;&#x000b1;&#x02009;3.1</td><td>2.8&#x02009;&#x000b1;&#x02009;2.5</td><td>0.104<sup>c</sup></td></tr><tr><td>&#x02003;POMS-vigor</td><td>7.7&#x02009;&#x000b1;&#x02009;4.1</td><td>7.2&#x02009;&#x000b1;&#x02009;3.6</td><td>6.1&#x02009;&#x000b1;&#x02009;3.5</td><td>0.179<sup>c</sup></td></tr><tr><td>&#x02003;POMS-fatigue</td><td>6.8&#x02009;&#x000b1;&#x02009;4.4</td><td>7.8&#x02009;&#x000b1;&#x02009;4.3</td><td>6.4&#x02009;&#x000b1;&#x02009;3.6</td><td>0.727<sup>c</sup></td></tr><tr><td>&#x02003;POMS-confusion</td><td>5.0&#x02009;&#x000b1;&#x02009;2.8</td><td>4.8&#x02009;&#x000b1;&#x02009;2.4</td><td>3.8&#x02009;&#x000b1;&#x02009;2.2</td><td>0.323<sup>c</sup></td></tr><tr><td colspan="5">Body composition</td></tr><tr><td>&#x02003;Height, cm</td><td>157.6&#x02009;&#x000b1;&#x02009;4.6</td><td>158.4&#x02009;&#x000b1;&#x02009;5.1</td><td>158.0&#x02009;&#x000b1;&#x02009;3.8</td><td>0.817<sup>a</sup></td></tr><tr><td>&#x02003;Weight, kg</td><td>52.8&#x02009;&#x000b1;&#x02009;7.5</td><td>52.6&#x02009;&#x000b1;&#x02009;6.0</td><td>58.3&#x02009;&#x000b1;&#x02009;11.1</td><td>0.018<sup>a</sup></td></tr><tr><td>&#x02003;Body mass index, kg/cm<sup>2</sup></td><td>21.2&#x02009;&#x000b1;&#x02009;2.8</td><td>21.0&#x02009;&#x000b1;&#x02009;2.5</td><td>23.3&#x02009;&#x000b1;&#x02009;4.0</td><td>0.012<sup>a</sup></td></tr><tr><td>&#x02003;Body fat mass, kg</td><td>14.0&#x02009;&#x000b1;&#x02009;5.1</td><td>13.7&#x02009;&#x000b1;&#x02009;4.4</td><td>18.5&#x02009;&#x000b1;&#x02009;8.5</td><td>0.008<sup>a</sup></td></tr><tr><td>&#x02003;Fat free mass, kg</td><td>36.5&#x02009;&#x000b1;&#x02009;2.8</td><td>36.6&#x02009;&#x000b1;&#x02009;2.2</td><td>37.6&#x02009;&#x000b1;&#x02009;2.8</td><td>0.222<sup>a</sup></td></tr><tr><td>&#x02003;Waist:hip ratio, %</td><td>80.6&#x02009;&#x000b1;&#x02009;6.1</td><td>81.7&#x02009;&#x000b1;&#x02009;4.8</td><td>83.4&#x02009;&#x000b1;&#x02009;6.2</td><td>0.191<sup>a</sup></td></tr><tr><td>&#x02003;Body temperature, &#x000b0;C</td><td>36.3&#x02009;&#x000b1;&#x02009;0.33</td><td>36.4&#x02009;&#x000b1;&#x02009;0.42</td><td>36.3&#x02009;&#x000b1;&#x02009;0.41</td><td>0.701<sup>a</sup></td></tr><tr><td char="&#x000d7;" align="char" colspan="5">Cardiovascular parameters</td></tr><tr><td>&#x02003;Systolic blood pressure, mmHg</td><td>122.7&#x02009;&#x000b1;&#x02009;15.7</td><td>119.3&#x02009;&#x000b1;&#x02009;16.1</td><td>119.9&#x02009;&#x000b1;&#x02009;13.6</td><td>0.668<sup>a</sup></td></tr><tr><td>&#x02003;Diastolic blood pressure, mmHg</td><td>69.2&#x02009;&#x000b1;&#x02009;12.1</td><td>67.8&#x02009;&#x000b1;&#x02009;13.6</td><td>68.7&#x02009;&#x000b1;&#x02009;13.6</td><td>0.919<sup>a</sup></td></tr><tr><td>&#x02003;Heart rate, beats/min</td><td>77.2&#x02009;&#x000b1;&#x02009;8.0</td><td>76.9&#x02009;&#x000b1;&#x02009;12.7</td><td>80.1&#x02009;&#x000b1;&#x02009;12.4</td><td>0.504<sup>a</sup></td></tr><tr><td>&#x02003;Cardio-ankle vascular index</td><td>7.19&#x02009;&#x000b1;&#x02009;0.79</td><td>7.24&#x02009;&#x000b1;&#x02009;0.79</td><td>7.14&#x02009;&#x000b1;&#x02009;0.78</td><td>0.967<sup>a</sup></td></tr><tr><td align="justify" colspan="5">Actigraphy</td></tr><tr><td>&#x02003;Active ZC (/min)</td><td>156.6&#x02009;&#x000b1;&#x02009;26.2</td><td>148.0&#x02009;&#x000b1;&#x02009;31.8</td><td>149.0&#x02009;&#x000b1;&#x02009;34.0</td><td>0.506<sup>a</sup></td></tr><tr><td>&#x02003;Sleep ZC (/min)</td><td>4.3&#x02009;&#x000b1;&#x02009;1.1</td><td>4.3&#x02009;&#x000b1;&#x02009;1.8</td><td>4.7&#x02009;&#x000b1;&#x02009;1.7</td><td>0.606<sup>a</sup></td></tr><tr><td>&#x02003;Active METs</td><td>1.6&#x02009;&#x000b1;&#x02009;0.15</td><td>1.5&#x02009;&#x000b1;&#x02009;0.14</td><td>1.6&#x02009;&#x000b1;&#x02009;0.21</td><td>0.674<sup>a</sup></td></tr><tr><td>&#x02003;Sleep METs</td><td>1.1&#x02009;&#x000b1;&#x02009;0.015</td><td>1.1&#x02009;&#x000b1;&#x02009;0.015</td><td>1.1&#x02009;&#x000b1;&#x02009;0.019</td><td>0.580<sup>a</sup></td></tr><tr><td>&#x02003;Sleep time (min/day)</td><td>372.1&#x02009;&#x000b1;&#x02009;70.6</td><td>371.4&#x02009;&#x000b1;&#x02009;60,6</td><td>367.8&#x02009;&#x000b1;&#x02009;54.8</td><td>0.687<sup>a</sup></td></tr><tr><td>&#x02003;Sleep efficiency (%)</td><td>97.2&#x02009;&#x000b1;&#x02009;1.4</td><td>97.4&#x02009;&#x000b1;&#x02009;1.7</td><td>97.5&#x02009;&#x000b1;&#x02009;1.8</td><td>0.719<sup>a</sup></td></tr><tr><td>&#x02003;Episodes of nocturnal awakening (&#x0003e;1&#x000a0;min) (/day)</td><td>1.7&#x02009;&#x000b1;&#x02009;1.2</td><td>1.8&#x02009;&#x000b1;&#x02009;1.4</td><td>1.8&#x02009;&#x000b1;&#x02009;1.5</td><td>0.676<sup>a</sup></td></tr><tr><td colspan="5">Lifestyle factors, %</td></tr><tr><td>&#x02003;Exercising regularly</td><td>50.0</td><td>46.7</td><td>51.9</td><td>0.923<sup>b</sup></td></tr><tr><td>&#x02003;Smoking</td><td>6.25</td><td>10.0</td><td>7.4</td><td>0.856<sup>b</sup></td></tr><tr><td>&#x02003;Drinking alcohol (daily / by chance / not at all)</td><td>15.6 / 68.8 / 15.6</td><td>20.0 / 63.3 / 16.7</td><td>29.6 / 59.3 / 11.1</td><td>0.749<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p>Values are presented as mean&#x02009;&#x000b1;&#x02009;SD unless otherwise indicated</p><p><italic>AIS</italic> Athens Insomnia Scale, <italic>CAVI</italic> cardio-ankle vascular index, <italic>HADS</italic> Hospital Anxiety and Depression Scale, <italic>METs</italic> metabolic equivalents, <italic>MHR-QOL</italic> Menopausal Health-Related Quality of Life, <italic>POMS</italic> Profile of Mood States, <italic>ZC</italic>, zero-crossing</p><p><sup>a</sup>One-way analysis of variance</p><p><sup>b</sup>Chi-square test</p><p><sup>c</sup>Kruskal-Wallis test</p></table-wrap-foot></table-wrap></p><p id="Par31">The mean&#x02009;&#x000b1;&#x02009;SEM CFS scores significantly decreased after 8&#x000a0;weeks of treatment in all the groups, and there were no significant differences among the groups (placebo vs low-dose vs high-dose groups: &#x02212;2.9&#x02009;&#x000b1;&#x02009;1.1, &#x02212;3.2&#x02009;&#x000b1;&#x02009;1.1, and &#x02212;3.5&#x02009;&#x000b1;&#x02009;1.0, respectively; <italic>P</italic>&#x02009;=&#x02009;0.79, Kruskal-Wallis test, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). After 8&#x000a0;weeks of treatment, the mean&#x02009;&#x000b1;&#x02009;SEM POMS-vigor score was significantly higher in the high-dose group than the placebo group (1.9&#x02009;&#x000b1;&#x02009;0.7 vs 0.2&#x02009;&#x000b1;&#x02009;0.6, respectively; <italic>P</italic>&#x02009;=&#x02009;0.02, Mann-Whitney test, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). The mean&#x02009;&#x000b1;&#x02009;SEM diastolic blood pressure (&#x02212;4.1&#x02009;&#x000b1;&#x02009;1.8 vs 1.2&#x02009;&#x000b1;&#x02009;1.9; <italic>P</italic>&#x02009;=&#x02009;0.05, unpaired t-test, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>) and CAVI (&#x02212;0.4&#x02009;&#x000b1;&#x02009;0.2 vs 0.07&#x02009;&#x000b1;&#x02009;0.1; <italic>P</italic>&#x02009;=&#x02009;0.03, unpaired t-test, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>) significantly decreased after 8&#x000a0;weeks of treatment in the high-dose group compared with the placebo group. Neither the body composition parameters nor the actigraphic parameters changed significantly in any of the groups (data not shown).<fig id="Fig2"><label>Fig. 2</label><caption><p>The changes from baseline after 8&#x000a0;weeks of intervention in: (<bold>a</bold>) the Chalder Fatigue Scale scores; (<bold>b</bold>) the Profile of Mood States (POMS)-vigor scores; (<bold>c</bold>) diastolic blood pressure; and (<bold>d</bold>) cardio-ankle vascular index (CAVI). Data are presented as means and standard errors. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs placebo, Mann-Whitney test or unpaired t-test</p></caption><graphic xlink:href="12937_2018_314_Fig2_HTML" id="MO2"/></fig></p><p id="Par32">During the whole study period, no treatment-emergent adverse event was reported by the participants, even though laboratory tests were not routinely performed.</p></sec><sec id="Sec11"><title>Discussion</title><p id="Par33">In this randomized, double-blind, placebo-controlled study, the effect of soy lecithin on menopausal symptoms including fatigue and other various health parameters in Japanese middle-aged women was investigated. The results showed that high-dose (1200&#x000a0;mg/day) soy lecithin not only increases vigor, but also lowers the diastolic blood pressure and CAVI in Japanese middle-aged women who complained of fatigue.</p><p id="Par34">LRT is a concept proposed by Nicolson et al. [<xref ref-type="bibr" rid="CR4">4</xref>]. The mitochondrion is the site where adenosine triphosphate (ATP) is synthesized aerobically, and the inner and outer membrane of the organelle are composed by phospholipids. Reactive oxygen species (ROS) are generated in the process of uncoupling the electron transport chain from ATP generation, with the inner mitochondrial membrane being the most important source of ROS [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. When mitochondrial membranes are damaged by ROS, energy production by the organelle is decreased, which could lead to fatigue, as well as aging and various diseases. In previous animal [<xref ref-type="bibr" rid="CR22">22</xref>] and clinical studies [<xref ref-type="bibr" rid="CR23">23</xref>], LRT was demonstrated to improve mitochondrial function assessed by transport and reduction of the dye Rhodamine-123, mitochondrial membrane potentials assessed by flow cytometry, and mitochondrial DNA deletions [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par35">Lecithin is particularly abundant in egg yolks, soybeans, organ and lean meats, and fish. The total phospholipids contained in 100&#x000a0;g of egg yolk and soybeans are 31.8&#x000a0;g and 20.8&#x000a0;g, respectively [<xref ref-type="bibr" rid="CR25">25</xref>], and the normal dietary intake of phospholipids is estimated as 2&#x02013;8&#x000a0;g per day [<xref ref-type="bibr" rid="CR26">26</xref>]. Most previous studies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] have used the dosage of 1 to 3&#x000a0;g per day of oral supplementation of lecithin, exhibiting its effects for inflammatory diseases, hyperlipidemia, cardiovascular diseases, cognitive impairment, and fatiguing illnesses. Oral administration of phospholipids has been shown to be generally safe [<xref ref-type="bibr" rid="CR4">4</xref>]. For example, in phase I and II clinical trials in patients with cardiovascular diseases, over 5&#x000a0;g of soy phospholipids were administered with no apparent toxicity [<xref ref-type="bibr" rid="CR27">27</xref>]. Referring to older studies, a daily dosage of as much as 54&#x000a0;g has been administered without any apparent adverse effects [<xref ref-type="bibr" rid="CR28">28</xref>]. Regarding the duration of the treatment, most of the previous studies investigating the effects of dietary LRT supplement on fatigue examined for 8&#x000a0;weeks, meanwhile some examined for 1 or 12&#x000a0;weeks [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par36">In this study, the effect of soy lecithin on fatigue and other factors was investigated, and our findings showed that lecithin promotes vigor assessed by the POMS-brief questionnaire. Previous studies have demonstrated the effect of phospholipids on cancer-associated fatigue and adverse chemotherapy effects, such as nausea, diarrhea, constipation, and fatigue [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], using NT Factor&#x000ae; (Nutritional Therapeutics, Inc., Hauppauge, NY.), an oral supplement containing phospholipids, glycolipids, and other membrane lipids [<xref ref-type="bibr" rid="CR23">23</xref>]. Feelings of fatigue and loss of vigor are similar and the difference is ambiguous, and our result can be understood in the same context. In this study, significant differences in the fatigue scores among the groups could not be shown. The reason for this may be the placebo effect because the fatigue scores were improved in all groups, and it was explained to the participants that lecithin might improve fatigue. Other reasons why the improvement of fatigue was not different among the groups might be that the participants were relatively healthy and the baseline fatigue scores were not high enough, or that some portion of the fatigue experienced by the participants was derived from pathological conditions, such as infection, inflammation, and sleep disorders.</p><p id="Par37">The present study also revealed that lecithin decreases the diastolic blood pressure and CAVI. The risk of cardiovascular diseases (CVDs), including central obesity, hypertension, dyslipidemia, and diabetes, increases after menopause [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>], partly as a result of diminished estrogen production [<xref ref-type="bibr" rid="CR35">35</xref>]. CVD is rare in young women, but it is the second leading cause of death among the 45&#x02013;64&#x000a0;year age group in the United States after cancer, and it has become the leading cause after the age of 65&#x000a0;years [<xref ref-type="bibr" rid="CR36">36</xref>]. Especially in women, the treatment of arterial hypertension and diabetes is considered important for the prevention of CVD [<xref ref-type="bibr" rid="CR37">37</xref>]. Several studies demonstrated that lecithin lowered total cholesterol in patients with primary hyperlipidemia [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], and a mini-pig study showed that LRT reduced atherosclerotic plaques in the aortas and heart valves [<xref ref-type="bibr" rid="CR40">40</xref>]. There is a possibility that lecithin lowers cardiovascular risks, although the mechanisms are yet to be elucidated. This is the first study showing the effects of lecithin on the diastolic blood pressure and CAVI. Further study is warranted to corroborate the findings and also to examine the effect on systolic blood pressure. In the present study, there was statistically significant differences in the baseline characteristics among the study groups, that is weight, body mass index, and body fat mass were significantly higher in the high-dose group. On the other hand, there was no significant difference in the POMS-vigor score, diastolic blood pressure, and CAVI that changed significantly after the 8-week treatment, therefore we consider that the differences in the baseline characteristics would have a small influence on the results of the present study.</p><p id="Par38">The present study has some limitations. First, the sample size was relatively small and the study period was as short as 8&#x000a0;weeks, and all the participants were relatively healthy women. Second, mitochondrial function was not evaluated, and the results could not be directly explained by the functional improvement of the mitochondria. Finally, we set the full dose as 1200&#x000a0;mg in this study, which might not be sufficient. Further studies with longer duration enrolling more patients with severe fatigue, hypertension, or established atherosclerosis are warranted in order to corroborate our findings concerning the effects of soy lecithin on vigor and cardiovascular risks. Higher doses of lecithin and simultaneous assessment of the mitochondrial function may be needed to evaluate the effects of the compound.</p></sec><sec id="Sec12"><title>Conclusions</title><p id="Par39">High-dose (1200&#x000a0;mg/day) soy lecithin not only increases vigor, but also lowers the diastolic blood pressure and CAVI in middle-aged women who present with fatigue. Further studies with longer duration enrolling more patients with severe fatigue are warranted in order to corroborate our findings.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AIS</term><def><p id="Par6">Athens insomnia scale</p></def></def-item><def-item><term>ATP</term><def><p id="Par7">Adenosine triphosphate</p></def></def-item><def-item><term>BFI</term><def><p id="Par8">Brief fatigue inventory</p></def></def-item><def-item><term>CAVI</term><def><p id="Par9">Cardio-ankle vascular index</p></def></def-item><def-item><term>CFS</term><def><p id="Par10">Chalder fatigue scale</p></def></def-item><def-item><term>CVD</term><def><p id="Par11">Cardiovascular disease</p></def></def-item><def-item><term>HADS</term><def><p id="Par12">Hospital anxiety and depression scale</p></def></def-item><def-item><term>LRT</term><def><p id="Par13">Lipid replacement therapy</p></def></def-item><def-item><term>MET</term><def><p id="Par14">Metabolic equivalent</p></def></def-item><def-item><term>MHR-QOL</term><def><p id="Par15">Menopausal health-related quality of life</p></def></def-item><def-item><term>POMS</term><def><p id="Par16">Profile of mood states</p></def></def-item><def-item><term>ROS</term><def><p id="Par17">Reactive oxygen species</p></def></def-item><def-item><term>ZC</term><def><p id="Par18">Zero-crossing</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par40">MT received an unrestricted research grant from Kikkoman Corporation.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par41">The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AH and MT were responsible for project development, data collection, and data analysis. YO, MA, and KK were responsible for data collection. NM participated in the project development and supervision. All authors contributed to reviewing, editing, and approving the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par42">The study protocol was reviewed and approved by the Tokyo Medical and Dental University Review Board, and written informed consent was obtained from all the participants.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par43">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par44">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par45">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>M</given-names></name><name><surname>Hiramitsu</surname><given-names>S</given-names></name><name><surname>Akiyoshi</surname><given-names>M</given-names></name><name><surname>Owa</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Obayashi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of the kampo formula tokishakuyakusan on headaches and concomitant depression in middle-aged women</article-title><source>Evid Based Complement Alternat Med</source><year>2014</year><volume>2014</volume><fpage>593560</fpage><pub-id pub-id-type="doi">10.1155/2014/593560</pub-id><pub-id pub-id-type="pmid">24648849</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Yoshizawa</surname><given-names>T</given-names></name><name><surname>Gollschewski</surname><given-names>S</given-names></name><name><surname>Atogami</surname><given-names>F</given-names></name><name><surname>Courtney</surname><given-names>M</given-names></name></person-group><article-title>Menopause in Australia and Japan: effects of country of residence on menopausal status and menopausal symptoms</article-title><source>Climacteric</source><year>2004</year><volume>7</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1080/13697130410001713760</pub-id><pub-id pub-id-type="pmid">15497905</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cath&#x000e9;bras</surname><given-names>PJ</given-names></name><name><surname>Robbins</surname><given-names>JM</given-names></name><name><surname>Kirmayer</surname><given-names>LJ</given-names></name><name><surname>Hayton</surname><given-names>BC</given-names></name></person-group><article-title>Fatigue in primary care: prevalence, psychiatric comorbidity, illness behavior, and outcome</article-title><source>J Gen Intern Med</source><year>1992</year><volume>7</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/BF02598083</pub-id><pub-id pub-id-type="pmid">1613608</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolson</surname><given-names>GL</given-names></name><name><surname>Ash</surname><given-names>ME</given-names></name></person-group><article-title>Lipid replacement therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function</article-title><source>Biochim Biophys Acta</source><year>1838</year><volume>2014</volume><fpage>1657</fpage><lpage>1679</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevchenko</surname><given-names>A</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name></person-group><article-title>Lipidomics: coming to grips with lipid diversity</article-title><source>Nat Rev Mol Cell Biol.</source><year>2010</year><volume>11</volume><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/nrm2934</pub-id><pub-id pub-id-type="pmid">20606693</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Meer</surname><given-names>G</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Feigenson</surname><given-names>GW</given-names></name></person-group><article-title>Membrane lipids: where they are and how they behave</article-title><source>Nat Rev Mol Cell Biol</source><year>2008</year><volume>9</volume><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nrm2330</pub-id><pub-id pub-id-type="pmid">18216768</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000fc;llenberg</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>LA</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Massing</surname><given-names>U</given-names></name></person-group><article-title>Health effects of dietary phospholipids</article-title><source>Lipids Health Dis</source><year>2012</year><volume>11</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-11-3</pub-id><pub-id pub-id-type="pmid">22221489</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>M</given-names></name><name><surname>Horiguchi</surname><given-names>N</given-names></name><name><surname>Kajiyama</surname><given-names>A</given-names></name><name><surname>Akiyoshi</surname><given-names>M</given-names></name><name><surname>Owa</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of grape seed proanthocyanidin extract on menopausal symptoms, body composition, and cardiovascular parameters in middle-aged women: a randomized, double-blind, placebo-controlled pilot study</article-title><source>Menopause</source><year>2014</year><volume>21</volume><fpage>990</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1097/GME.0000000000000200</pub-id><pub-id pub-id-type="pmid">24518152</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>M</given-names></name><name><surname>Obayashi</surname><given-names>S</given-names></name><name><surname>Akiyoshi</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Matsushima</surname><given-names>E</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name></person-group><article-title>Insomnia in Japanese peri- and postmenopausal women</article-title><source>Climacteric</source><year>2010</year><volume>13</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.3109/13697130903353478</pub-id><pub-id pub-id-type="pmid">19886814</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>M</given-names></name><name><surname>Battersby</surname><given-names>R</given-names></name><name><surname>Whitehead</surname><given-names>M</given-names></name></person-group><article-title>Relationships between psychological symptoms, somatic complaints and menopausal status</article-title><source>Maturitas</source><year>1986</year><volume>8</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/0378-5122(86)90029-0</pub-id><pub-id pub-id-type="pmid">3784918</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>M</given-names></name></person-group><article-title>The south-east England longitudinal study of the climacteric and postmenopause</article-title><source>Maturitas</source><year>1992</year><volume>14</volume><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/0378-5122(92)90004-N</pub-id><pub-id pub-id-type="pmid">1565020</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr Scand</source><year>1983</year><volume>67</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1983.tb09716.x</pub-id><pub-id pub-id-type="pmid">6880820</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name></person-group><article-title>The hospital anxiety and depression scale (in Japanese)</article-title><source>Seisinka-Sindangaku</source><year>1993</year><volume>4</volume><fpage>371</fpage><lpage>372</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldatos</surname><given-names>CR</given-names></name><name><surname>Dikeos</surname><given-names>DG</given-names></name><name><surname>Paparrigopoulos</surname><given-names>TJ</given-names></name></person-group><article-title>Athens insomnia scale: validation of an instrument based on ICD-10 criteria</article-title><source>J Psychosom Res</source><year>2000</year><volume>48</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/S0022-3999(00)00095-7</pub-id><pub-id pub-id-type="pmid">11033374</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeun</surname><given-names>EJ</given-names></name><name><surname>Shin-Park</surname><given-names>KK</given-names></name></person-group><article-title>Verification of the profile of mood states-brief: cross-cultural analysis</article-title><source>J Clin Psychol</source><year>2006</year><volume>62</volume><fpage>1173</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1002/jclp.20269</pub-id><pub-id pub-id-type="pmid">16688705</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Araki</surname><given-names>S</given-names></name><name><surname>Kawakami</surname><given-names>N</given-names></name><name><surname>Tkakeshita</surname><given-names>T</given-names></name></person-group><article-title>Production of the Japanese edition of profile of mood states (POMS): assessment of reliability and validity</article-title><source>Nihon Koshu Eisei Zasshi</source><year>1990</year><volume>37</volume><fpage>913</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">2132363</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalder</surname><given-names>T</given-names></name><name><surname>Berelowitz</surname><given-names>G</given-names></name><name><surname>Pawlikowska</surname><given-names>T</given-names></name><name><surname>Watts</surname><given-names>L</given-names></name><name><surname>Wessely</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development of a fatigue scale</article-title><source>J Psychosom Res</source><year>1993</year><volume>37</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/0022-3999(93)90081-P</pub-id><pub-id pub-id-type="pmid">8463991</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>C</given-names></name></person-group><article-title>The Chalder fatigue scale (CFQ 11)</article-title><source>Occup Med (Lond)</source><year>2015</year><volume>65</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1093/occmed/kqu168</pub-id><pub-id pub-id-type="pmid">25559796</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>TR</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Morrissey</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Wendt</surname><given-names>JK</given-names></name><etal/></person-group><article-title>The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory</article-title><source>Cancer</source><year>1999</year><volume>85</volume><fpage>1186</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19990301)85:5&#x0003c;1186::AID-CNCR24&#x0003e;3.0.CO;2-N</pub-id><pub-id pub-id-type="pmid">10091805</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuyama</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name><name><surname>Akechi</surname><given-names>T</given-names></name><name><surname>Mendoza</surname><given-names>TR</given-names></name><name><surname>Hosaka</surname><given-names>T</given-names></name><name><surname>Cleeland</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Validation study of the Japanese version of the brief fatigue inventory</article-title><source>J Pain Symptom Manag</source><year>2003</year><volume>25</volume><fpage>106</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0885-3924(02)00596-1</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalogeris</surname><given-names>T</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Korthuis</surname><given-names>RJ</given-names></name></person-group><article-title>Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning</article-title><source>Redox Biol</source><year>2014</year><volume>2</volume><fpage>702</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2014.05.006</pub-id><pub-id pub-id-type="pmid">24944913</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidman</surname><given-names>MD</given-names></name><name><surname>Khan</surname><given-names>MJ</given-names></name><name><surname>Tang</surname><given-names>WX</given-names></name><name><surname>Quirk</surname><given-names>WS</given-names></name></person-group><article-title>Influence of lecithin on mitochondrial DNA and age-related hearing loss</article-title><source>Otolaryngol Head Neck Surg</source><year>2002</year><volume>127</volume><fpage>138</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1067/mhn.2002.127627</pub-id><pub-id pub-id-type="pmid">12297801</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agadjanyan</surname><given-names>M</given-names></name><name><surname>Vasilevko</surname><given-names>V</given-names></name><name><surname>Ghochikyan</surname><given-names>A</given-names></name><name><surname>Berns</surname><given-names>P</given-names></name><name><surname>Kesslak</surname><given-names>P</given-names></name><name><surname>Settineri</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Nutritional supplement (NT factor&#x02122;) restores mitochondrial function and reduces moderately severe fatigue in aged subjects</article-title><source>J Chronic Fatigue Syndr</source><year>2003</year><volume>11</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1300/J092v11n03_03</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>DD</given-names></name><name><surname>Hayes</surname><given-names>SF</given-names></name><name><surname>Spangrude</surname><given-names>GJ</given-names></name></person-group><article-title>Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux</article-title><source>Blood</source><year>1998</year><volume>91</volume><fpage>4106</fpage><lpage>4117</lpage><pub-id pub-id-type="pmid">9596656</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>JS</given-names></name><name><surname>Kamili</surname><given-names>A</given-names></name><name><surname>Wat</surname><given-names>E</given-names></name><name><surname>Chung</surname><given-names>RW</given-names></name><name><surname>Tandy</surname><given-names>S</given-names></name></person-group><article-title>Dietary phospholipids and intestinal cholesterol absorption</article-title><source>Nutrients</source><year>2010</year><volume>2</volume><fpage>116</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.3390/nu2020116</pub-id><pub-id pub-id-type="pmid">22254012</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>JS</given-names></name><name><surname>Wat</surname><given-names>E</given-names></name><name><surname>Kamili</surname><given-names>A</given-names></name><name><surname>Tandy</surname><given-names>S</given-names></name></person-group><article-title>Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease</article-title><source>Curr Opin Lipidol</source><year>2008</year><volume>19</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1097/MOL.0b013e3282ffaf96</pub-id><pub-id pub-id-type="pmid">18460916</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>NR</given-names></name><name><surname>Sparks</surname><given-names>DL</given-names></name></person-group><article-title>Phospholipids as cardiovascular therapeutics</article-title><source>Curr Opin Investig Drugs</source><year>2008</year><volume>9</volume><fpage>281</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">18311664</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuiman</surname><given-names>JT</given-names></name><name><surname>Beynen</surname><given-names>AC</given-names></name><name><surname>Katan</surname><given-names>MB</given-names></name></person-group><article-title>Lecithin intake and serum cholesterol</article-title><source>Am J Clin Nutr</source><year>1989</year><volume>49</volume><fpage>266</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">2916447</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolson</surname><given-names>GL</given-names></name><name><surname>Ellithorpe</surname><given-names>R</given-names></name></person-group><article-title>Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses</article-title><source>Chronic Fatigue Syndr</source><year>2006</year><volume>13</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1300/J092v13n01_06</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolson</surname><given-names>GL</given-names></name><name><surname>Conklin</surname><given-names>KA</given-names></name></person-group><article-title>Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy</article-title><source>Clin Exp Metastasis</source><year>2008</year><volume>25</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1007/s10585-007-9129-z</pub-id><pub-id pub-id-type="pmid">18058028</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>MC</given-names></name></person-group><article-title>The emergence of the metabolic syndrome with menopause</article-title><source>J Clin Endocrinol Metab</source><year>2003</year><volume>88</volume><fpage>2404</fpage><lpage>2411</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-030242</pub-id><pub-id pub-id-type="pmid">12788835</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname><given-names>GM</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Tulli</surname><given-names>A</given-names></name></person-group><article-title>Managing cardiovascular risk in menopausal women</article-title><source>Climacteric</source><year>2006</year><volume>9</volume><issue>Suppl 1</issue><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1080/13697130600917732</pub-id><pub-id pub-id-type="pmid">16899440</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lizcano</surname><given-names>F</given-names></name><name><surname>Guzm&#x000e1;n</surname><given-names>G</given-names></name></person-group><article-title>Estrogen deficiency and the origin of obesity during menopause</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>757461</fpage><pub-id pub-id-type="doi">10.1155/2014/757461</pub-id><pub-id pub-id-type="pmid">24734243</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Rosano</surname><given-names>G</given-names></name><name><surname>Casey</surname><given-names>C</given-names></name><name><surname>Daly</surname><given-names>C</given-names></name><name><surname>Gambacciani</surname><given-names>M</given-names></name><name><surname>Hadji</surname><given-names>P</given-names></name><etal/></person-group><article-title>Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>2028</fpage><lpage>2040</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehm296</pub-id><pub-id pub-id-type="pmid">17644507</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosano</surname><given-names>GM</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Marazzi</surname><given-names>G</given-names></name><name><surname>Volterrani</surname><given-names>M</given-names></name></person-group><article-title>Menopause and cardiovascular disease: the evidence</article-title><source>Climacteric</source><year>2007</year><volume>10</volume><issue>Suppl 1</issue><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1080/13697130601114917</pub-id><pub-id pub-id-type="pmid">17364594</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Leading Causes of Death in Females. Centers for Disease Control and Prevention. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_women_heart.htm">https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_women_heart.htm</ext-link> Accessed 1 Aug 2017.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Miceli</surname><given-names>M</given-names></name><name><surname>Rosano</surname><given-names>GM</given-names></name></person-group><article-title>Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention</article-title><source>Climacteric</source><year>2007</year><volume>10</volume><issue>Suppl 2</issue><fpage>16</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1080/13697130701602712</pub-id><pub-id pub-id-type="pmid">17882667</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>LA</given-names></name><name><surname>Hickie</surname><given-names>JB</given-names></name><name><surname>Ruys</surname><given-names>J</given-names></name></person-group><article-title>Treatment of hypercholesterolaemia with oral lecithin</article-title><source>Aust NZ J Med</source><year>1977</year><volume>7</volume><fpage>262</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/j.1445-5994.1977.tb03683.x</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcicki</surname><given-names>J</given-names></name><name><surname>Pawlik</surname><given-names>A</given-names></name><name><surname>Samochowiec</surname><given-names>L</given-names></name><name><surname>Kaldonska</surname><given-names>M</given-names></name><name><surname>Mysliwiec</surname><given-names>Z</given-names></name></person-group><article-title>Clinical evaluation of lecithin as a lipid-lowering agent</article-title><source>Phytother Res</source><year>1995</year><volume>9</volume><fpage>597</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1002/ptr.2650090814</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samochowiec</surname><given-names>L</given-names></name><name><surname>Kadlubowska</surname><given-names>D</given-names></name><name><surname>Rozewicka</surname><given-names>L</given-names></name><name><surname>Kuzna</surname><given-names>W</given-names></name><name><surname>Szyszka</surname><given-names>K</given-names></name></person-group><article-title>Investigations in experimental atherosclerosis .2. Effect of phosphatidylcholine (EPL) on experimental atherosclerotic changes in miniature pigs</article-title><source>Atherosclerosis</source><year>1976</year><volume>23</volume><fpage>319</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/0021-9150(76)90106-4</pub-id></element-citation></ref></ref-list></back></article>